Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
45 hedge funds and large institutions have $108M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 19 closing their positions.
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
25% less funds holding
Funds holding: 60 → 45 (-15)
35% less capital invested
Capital invested by funds: $167M → $108M (-$59.2M)
66% less call options, than puts
Call options by funds: $87K | Put options by funds: $259K
79% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$757K |
| 2 |
SC
Samlyn Capital
New York
|
+$700K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$658K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$584K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$290K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.33M |
| 2 |
Two Sigma Investments
New York
|
-$883K |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$832K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$817K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$495K |
STSA Hedge Fund Activity: Q3 2021 in Review
45 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q3 2021, worth a combined $108M — down 35% from $167M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of STSA and 4 opened new positions — a net loss of 15 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Nan Fung Group Holdings, opening a new position worth an estimated $757K. The largest seller was Morgan Stanley, cutting an estimated $1.33M.
- 45 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q3 2021, down from 60 in Q2 2021.
- Funds reported $108M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 35% quarter-over-quarter.
- 4 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 19 closed out, a net change of -15 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Nan Fung Group Holdings, an estimated $757K added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Morgan Stanley, an estimated $1.33M sold.
Based on aggregated 13F filings for Q3 2021.